Similar articles

• Molecular implications of the antiandrogen withdrawal syndrome.

  Moul JW, Srivastava S, McLeod DG. Moul JW, et al. Semin Urol. 1995 May;13(2):157-63. Semin Urol. 1995. PMID: 7543690 Review. No abstract available.
• Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

  Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM Jr, Bueschen AJ, Lowe BA. Eisenberger MA, et al. N Engl J Med. 1998 Oct 8;339(15):1036-42. doi: 10.1056/NEJM199810083391504. N Engl J Med. 1998. PMID: 9761805 Clinical Trial.
• [Fulminant liver failure induced by flutamide].

  Rodríguez Gómez SJ, Martínez Moreno J, Martín Arribas MI, Pérez Villoria A, De la Serna Higuera C, Betancourt González A. Rodríguez Gómez SJ, et al. Rev Esp Enferm Dig. 2000 Jun;92(6):411. Rev Esp Enferm Dig. 2000. PMID: 10985104 Spanish. No abstract available.
• [Antiandrogen withdrawal syndrome in hormone refractory metastatic prostate cancer].

  Coutant G, Algayres JP, Dordain ML, Selle F, Le Berruyer PY, Bili H, Daly JP. Coutant G, et al. Rev Med Interne. 1997;18(9):732-4. doi: 10.1016/s0248-8663(97)83757-5. Rev Med Interne. 1997. PMID: 9365728 French. No abstract available.
• Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer.

  Kelly WK. Kelly WK. Eur Urol. 1998;34 Suppl 3:18-23. doi: 10.1159/000052292. Eur Urol. 1998. PMID: 9854191 Review.